Tenax Therapeutics Inc

NASDAQ: TENX    
Share price (4/24/24): $3.56    
Market cap (4/24/24): $6.301 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 5 pages Certain Information Identified With the Mark “[***]” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Third Amendment to the License Agreement of September 20, 2013
12/34/56
EX-10.2
from 8-K 30 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 15 pages Placement Agency Agreement February 8, 2024
12/34/56
EX-10.26
from S-1/A 16 pages Placement Agency Agreement [•], 2024
12/34/56
EX-10.25
from S-1/A 31 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 3 pages Lease Termination Agreement
12/34/56
EX-10.3
from 8-K 4 pages Leak-Out Agreement
12/34/56
EX-10.2
from 8-K 27 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 16 pages Placement Agency Agreement February 3, 2023
12/34/56
EX-10.30
from S-1/A 5 pages Leak-Out Agreement
12/34/56
EX-10.29
from S-1/A 27 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 2 pages [Signature Page Follows] 1
12/34/56
EX-10.2
from 8-K 10 pages Tenax Therapeutics, Inc. 2022 Stock Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.1
from 8-K 23 pages Tenax Therapeutics, Inc. 2022 Stock Incentive Plan 2022 Stock Incentive Plan Approved by the Board and Stockholders on April 8, 2022 and June 9, 2022, Respectively
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 42 pages Securities Purchase Agreement for Units
12/34/56
EX-10.22
from 10-K 6 pages Consulting Agreement
12/34/56
EX-10.21
from 10-K 9 pages Separation and Release Agreement
12/34/56
EX-10.20
from 10-K 6 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 3 pages Amendment to the License Agreement of September 20, 2013
12/34/56